Review of General Biologics and Licensing Regulations

Riepilogo

The Food and Drug Administration (FDA) is conducting a review of certain general biologics and licensing regulations and is requesting public comment on these regulations. This review is intended to identify regulations that are outdated, burdensome, inefficient, or otherwise unsuitable or unnecessary from a regulatory standpoint and in need of revision. This review is part of FDA's program to periodically review existing significant regulations. A request for comments on certain regulations for blood establishments and blood products will be published elsewhere in this issue of the Federal Register.